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Abstract
Aims/hypothesis The natural history and physiological
determinants of glucose intolerance in subjects living in
Europe have not been investigated. The aim of this study
was to increase our understanding of this area.
Methods We analysed the data from a population-based
cohort of 1,048 non-diabetic, normotensive men and
women (aged 30–60 years) in whom insulin sensitivity
was measured by the glucose clamp technique (M/I
index; average glucose infusion rate/steady-state insulin
concentration) and beta cell function was estimated by
mathematical modelling of the oral glucose tolerance test
at baseline and 3 years later.
Results Seventy-seven per cent of the participants had
normal glucose tolerance (NGT) and 5% were glucose
intolerant both at baseline and follow up; glucose tolerance
worsened in 13% (progressors) and improved in 6%
(regressors). The metabolic phenotype of the latter three
groups was similar (higher prevalence of familial diabetes,
older age, higher waist-to-hip ratio, higher fasting and 2 h
plasma glucose, higher fasting and 2 h plasma insulin,
lower insulin sensitivity and reduced beta cell glucose
sensitivity with increased absolute insulin secretion).
Adjusting for these factors in a logistic model, progression
was predicted by insulin resistance (bottom M/I quartile,
OR 2.52 [95% CI 1.51–4.21]) and beta cell glucose
insensitivity (bottom quartile, OR 2.39 [95% CI 1.6–
3.93]) independently of waist-to-hip ratio (OR 1.44 [95%
CI 1.13–1.84] for one SD). At follow up, insulin sensitivity
and beta cell glucose sensitivity were unchanged in the
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stable NGT and stable non-NGT groups, worsened in
progressors and improved in regressors.
Conclusions/interpretation Glucose tolerance deteriorates
over time in young, healthy Europids. Progressors, regres-
sors and glucose-intolerant participants share a common
baseline phenotype. Insulin sensitivity and beta cell glucose
sensitivity predict and track changes in glucose tolerance
independently of sex, age and obesity.
Keywords Beta cell function . Diabetes . Dysglycaemia
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Abbreviations
AIR Acute insulin response
CVD Cardiovascular disease
DPP Diabetes Prevention Program
FFM Fat-free mass
IFG Impaired fasting glycaemia
IGT Impaired glucose tolerance
IRAS Insulin Resistance Atherosclerosis Study
NGT Normal glucose tolerance
OGIS Oral Glucose Insulin Sensitivity
RISC Relationship between Insulin Sensitivity
and Cardiovascular
Introduction
Individuals with impaired glucose tolerance (IGT) or
impaired fasting glycaemia (IFG) are at increased risk of
developing overt type 2 diabetes [1]. On the other hand,
individuals with normal glucose tolerance (NGT) may also
progress to diabetes over time [2]. However, IGT and IFG
may be transient dysglycaemic states [1] and progression of
NGT to diabetes may be found to follow a non-linear time
trajectory when glucose tolerance is tested serially [3–5].
Thus, it has been argued that the variability of glucose
tolerance testing is such that regression from dysglycaemia
to normoglycaemia is an equally likely occurrence as the
reverse process, making the category of IGT a ‘diagnostic
ragbag’ [1].
What factors influence spontaneous changes in glucose
tolerance in non-diabetic individuals remains incompletely
understood. Among 241 people with ‘borderline diabetes’
in the Bedford Survey [6], the levels of blood glucose at
baseline were the main predictor of worsening to diabetes,
but glucose tolerance improved in half of the participants.
In an observational 8–10 year follow-up study of middle-
aged Swedish participants, among 280 participants with
IGT/IFG, lower glucose levels—fasting and post-glucose—
predicted reversal to NGT [7]. In the Diabetes Prevention
Program (DPP), lower glucose levels predicted restoration
of normal glucose regulation in participants with abnormal
glucose levels [8]. Thus, fasting plasma glucose concen-
trations and glucose levels 2 h following a standard OGTT
consistently track either progression or regression.
Prospective data on the chief physiological determinants
of glucose tolerance, that is, insulin sensitivity and beta cell
function, have been obtained using various techniques in
diverse groups of people, thereby arriving at somewhat
variable conclusions. Early studies in 155 white offspring
of type 2 diabetic patients identified reduced glucose
clearance on the IVGTT and hyperinsulinaemia as the
antecedents of overt type 2 diabetes, implicating insulin
resistance as the primary defect [9]. A 25 year follow-up
analysis of the same cohort using minimal model analysis
of the IVGTT likewise concluded that defects in both
insulin-dependent and insulin-independent glucose uptake
precede and predict diabetes and that the defects are
detectable when patients are normoglycaemic [10]. At
about the same time, a study carried out in 200 young,
obese Pima Indians using the euglycaemic hyperinsulinae-
mic clamp to measure insulin sensitivity reported that
insulin resistance was the strongest predictor of incident
diabetes among both NGT and IGT individuals, with the
acute insulin response (AIR) to glucose on the IVGTT
being an additional significant predictor only after adjusting
for obesity and insulin resistance [11]. In a subsequent
report on 34 Pima Indians studied sequentially over
∼5 years, both insulin resistance and AIR predicted
deterioration of glucose tolerance independently of one
another [12]. The Insulin Resistance Atherosclerosis Study
(IRAS) [13] employed the frequently sampled IVGTT with
minimal model analysis to estimate insulin sensitivity (as
the SI index) and AIR in African-American and Hispanic-
American families and reported that both insulin resistance
and beta cell dysfunction predict incident type 2 diabetes
[14]. Finally, detailed studies in 72 Hispanic women with
gestational diabetes followed up for 15–30 months con-
cluded that insulin resistance and a low insulin response to
glucose were independently associated with subsequent
development of diabetes [15].
Data in homogeneous, population-based cohorts of
non-diabetic white subjects generated with the use of
techniques directly measuring an array of physiological
control variables are lacking. Moreover, no study has
analysed reversal of glucose intolerance from the same
dataset or has repeated physiological measurements at
follow up. We report here the findings obtained in the
follow-up phase of the Relationship between Insulin
Sensitivity and Cardiovascular disease (RISC) Study
[16], which assessed insulin sensitivity, using the clamp
technique, and multiple aspects of beta cell function in
1,308 accurately phenotyped non-diabetic participants
from Europe.
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Methods
Study participants and design RISC is a prospective,
observational, cohort study whose rationale and methodol-
ogy have been published previously [16]. In brief, partic-
ipants were recruited from those attending clinics and
laboratory personnel at 19 centres in 13 countries in Europe
(extending from Finland to Greece in latitude and from
Spain to Serbia in longitude), according to the following
inclusion criteria: men or women, aged between 30 and
60 years (stratified by sex and by age according to 10 year
age groups) and clinically healthy. Initial exclusion criteria
were: treatment for obesity, hypertension, lipid disorders or
diabetes, pregnancy, cardiovascular or chronic lung disease,
weight change of ≥5 kg in the last month, cancer (in the last
5 years) and renal failure. Exclusion criteria after screening
were: arterial blood pressure ≥140/90 mmHg, fasting
plasma glucose ≥7.0 mmol/l, 2 h plasma glucose (on a
standard, 75 g OGTT, performed in each participant)
≥11.0 mmol/l or known diabetes, total serum cholesterol
≥7.8 mmol/l, serum triacylglycerols ≥4.6 mmol/l and ECG
abnormalities. Thus, this cohort represents a healthier
segment of a European population. Baseline examinations
began in June 2002 and were completed in July 2005 and
included 1,538 participants who received an OGTT. Of these,
1,308 participants also received a euglycaemic hyperinsuli-
naemic clamp and constituted the baseline cohort; cross-
sectional data on this cohort have been published [17].
All 1,308 participants in the baseline cohort were
recalled 3 years later and 1,048 (80%) participated in the
follow-up evaluation. The baseline anthropometric and
metabolic characteristics of the 260 participants who were
lost to follow up were very similar to those of the
individuals who participated (data not shown). The
follow-up study included all baseline anthropometric
measurements and the OGTT.
Local Ethics Committee approval was obtained by each
recruiting centre. Volunteers were given detailed written
information on the study as well as a verbal explanation; all
provided informed consent.
Lifestyle and medical history Information was collected on
personal and family medical history of CVD, stroke,
hypertension and diabetes in first-degree relatives as well
as information on smoking and alcohol habits and physical
activity.
Physical examination Height was measured on a clinic
stadiometer, body weight and fat-free mass (FFM) were
evaluated by the TANITA bioimpedance balance (Tanita
International Division, UK). Waist, hip and thigh circum-
ferences were measured by tape according to a standardised
written protocol.
Physical activity Participants were fitted with a CSA Acti-
graph (MTI: Manufacturing Technology, Fort Walton Beach,
FL, USA) attached to a waist belt for 1 week. The Actigraph
is a small (43 g) single-channel recording accelerometer
capable of continuous data collection for up to 22 days. Data
are summated over 1 min periods and processed to evaluate
energy expenditure over the entire recording period as well
as periods of moderate and intense activity [18].
OGTT Following a 10–12 h overnight fast, blood samples
were taken before and 30, 60, 90 and 120 min into a 75 g
OGTT. The test was repeated at follow up.
Insulin clamp On a separate day within 1 week of the
OGTT, a euglycaemic hyperinsulinaemic clamp was per-
formed in all participants. Exogenous insulin was infused at
a rate of 240 pmol min−1 m−2 simultaneously with a
variable 20% dextrose infusion adjusted every 5–10 min to
maintain plasma glucose level within 0.8 mmol/l (±15%) of
the target glucose level (4.5–5.5 mmol/l).
IVGTT In 761 of the 1,048 participants with follow-up data,
at the end of the clamp and while the clamp was continued, a
glucose bolus (0.3 mg/kg body weight) was administered
over 1 min; plasma glucose and C-peptide concentrations
were measured at 2, 4, 6 and 8 min after the bolus.
Analytical procedures Blood samples were separated into
plasma and serum, divided into aliquots and stored at −80°C
for glucose, insulin, C-peptide and the serum lipid profile
determination. Samples were transported on dry ice at pre-
arranged intervals to central laboratories. Plasma glucose
was measured by the glucose oxidase technique. Serum
insulin was measured by a specific time-resolved immuno-
fluorometric assay (TR-IFMA) (AutoDELFIA Insulin kit,
Wallac, Turku, Finland), with the following assay character-
istics: detection limit >3 pmol/l, intra-assay and inter-assay
variation 1.7% and 3.5%, respectively. The intra-assay and
inter-assay coefficients of variation were <5% and <10%,
respectively. Serum total HDL and LDL-cholesterol were
assayed by standard techniques.
Data analysis Fat mass was obtained as the difference
between body weight and FFM. LDL-cholesterol concen-
trations were calculated using Friedewald’s formula. Glu-
cose tolerance was categorised into normal (NGT, fasting
plasma glucose <6.1 mmol/l and 2 h plasma glucose
<7.8 mmol/l), IGT (fasting glucose <7.0 mmol/l and 2 h
glucose ≥7.8 and <11.1 mmol/l) and diabetes (type 2
diabetes diagnosis, fasting glucose ≥7.0 mmol/l or 2 h
glucose ≥11.1 mmol/l or glucose-lowering treatment). IFG
was defined as a fasting glucose <7.0 and ≥6.1 mmol/l and
2 h glucose ≥7.8.
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Based on the observed changes of glucose tolerance at
follow up, participants were classified as ‘stable NGT’ (i.e.
NGT at both baseline and follow up), ‘stable non-NGT’ (i.e.
IFG or IGT at both baseline and follow up), ‘progressors’ (i.e.
those stepping up along the sequences NGT→IFG,
NGT→IGT, NGT→type 2 diabetes, IFG→IGT, IFG→type
2 diabetes, IGT→type 2 diabetes, between baseline and
follow up) and ‘regressors’ (i.e. participants stepping down
along the same sequences).
Insulin sensitivity was calculated as the ratio of the M
value (insulin-mediated whole body glucose disposal)
during the final 40 min of the 2 h clamp (normalised to
the FFM) to the mean plasma insulin concentration
measured during the same interval (M/I [average glucose
infusion rate/steady-state insulin concentration], in units of
μmol min−1 [kg FFM]−1[nmol/l]−1), as per previous
analyses [17]. Using the M value not normalised to FFM
yielded identical results. To allow comparison of baseline
and follow-up values, insulin sensitivity was also estimated
from the plasma glucose and insulin levels measured during
the OGTT with the use of the oral glucose insulin
sensitivity (OGIS) method, which has been validated
against the insulin clamp technique [19]. OGIS was
optimised for the RISC database by re-estimating the OGIS
equation variables based on the RISC database and the
original data and by normalising the estimate by lean body
mass rather than body surface area [19]. The adjusted OGIS
index represents glucose clearance (in ml min−1 [kg
FFM]−1) at an insulin concentration typical of the clamp
(∼600 pmol/l). In the current dataset, M/I and OGIS were
correlated with one another, with Spearman correlation
coefficients ranging between 0.48 and 0.68 (all p<0.0001)
in the four groups defined above, and the overall correlation
between the classical and the adjusted OGIS index was 0.85
(p<0.0001). Glucose and C-peptide area under the time-
concentration curve were calculated using the trapezium
rule. Actigraph readings were summarised as habitual
activity (average number of counts per minute worn) [18].
Beta cell function modelling The model used to reconstruct
insulin secretion and its control by glucose has been
previously described [20]. In brief, the model consists of
three blocks: (1) a model for fitting the glucose concentra-
tion profile, the purpose of which is to smooth and
interpolate plasma glucose concentrations; (2) a model
describing the dependence of insulin (or C-peptide)
secretion on glucose concentration; and (3) a model of C-
peptide kinetics, i.e. the two-exponential model proposed
by van Cauter et al. [21], in which the model parameters are
individually adjusted to the subject’s anthropometric data.
In particular, with regard to the insulin secretion block (b),
the relationship between insulin release and plasma glucose
concentration is modelled as the sum of two components.
The first component represents the dependence of insulin
secretion on absolute glucose concentration at any time
point, and is characterised by a dose–response function
relating the two variables. The characteristic parameter of
the dose–response is its mean slope in each individual’s
glucose range, denoted here as ‘glucose sensitivity’. The dose-
response is modulated by both glucose-mediated and non-
glucose-mediated factors (i.e. non-glucose substrates, gastro-
intestinal hormones and neurotransmitters), which are collec-
tivelymodelled as a potentiation factor. This factor is set to be a
positive function of time and to average one during the
experiment. The second insulin secretion component repre-
sents a dynamic dependence of insulin secretion on the rate of
change of glucose concentration. This component is known as
the derivative component, and is determined by a single
parameter, denoted as ‘rate sensitivity’. The model parameters
are determined from the glucose and C-peptide data under a
smoothness constraint on the potentiation factor. This approach
is similar to that usually employed for deconvolution of C-
peptide data, in which a smoothness constraint is imposed on
insulin secretion; the smoothness constraint is tuned so that the
C-peptide residual error is in the range of the assay precision.
The acute insulin response to the glucose bolus (AIR)
was calculated as the ratio of the mean incremental insulin
secretion (assessed by using C-peptide deconvolution [21])
during the first 8 min following the glucose bolus to the
mean incremental glucose concentration over the same time
interval; thus the units of AIR are pmol min−1m−2 (mmol/l)−1.
Baseline glucose values for calculating the increments were
those obtained at the end of the clamp [22].
Statistical analysis Data are presented as median and
interquartile range and were transformed into their natural
logarithm for use in parametric statistical testing. Partic-
ipants were grouped according to whether they were stable
NGT, regressors to NGT, stable non-NGT or progressors.
Group values were compared by the Mann–Whitney or the
Kruskal–Wallis test for continuous variables or χ2 for
nominal variables; paired values were compared using the
Wilcoxon test. General linear models were used to adjust
group comparisons for potential confounders (centre, sex,
age and BMI); when the group factor was significant,
individual group comparisons were performed using linear
contrasts. Simple associations were tested by Spearman’s
correlation coefficient. Logistic regression was used to
predict progression; using a multistage modelling approach,
association of each metabolic variable with progression was
first tested with adjustment for covariates, then the
metabolic variables were tested simultaneously. Odds ratios
were estimated per standard deviation increase in the
independent variable. Multiple regression analysis was carried
out using a forward stepwise model. A p value <0.05 was
considered statistically significant.
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Results
The general descriptors of the study cohort are given in
Table 1. In addition to the typical sex differences, insulin
sensitivity was ∼30% higher in women than in men. At
baseline, 25 participants had IFG (eight women, 17 men,
2.4%) and 94 had IGT (63 women, 31 men, 9.0%); at
follow up, 42 had IFG (4.0%), 123 (11.7%) had IGT and 15
(1.4%) had overt type 2 diabetes. Based on these changes,
809 (77%) of the participants were classified as stable
NGT and another 49 (5%) were stable non-NGT, while
glucose tolerance improved in 61 participants (6%,
regressors) and deteriorated in twice as many (129 or
13%, progressors). In the entire cohort, fasting plasma
glucose concentrations at follow up were significantly
higher than at baseline (5.22 vs 5.09 mmol/l, p<0.0001,
a 1%/year rise) as were glucose levels 2 h following
glucose ingestion (5.93 vs 5.72 mmol/l, p<0.0001, a 2%/
year rise). The plasma glucose responses to oral glucose at
baseline and follow up are shown in electronic supple-
mentary material (ESM) Fig. 1 separately for the four
groups. The majority of progressors (∼90%) originated
from the group who were NGT at baseline (which
represented 89% of the entire cohort). The baseline fasting
and 2 h plasma glucose levels (5.31 and 6.00 mmol/l) of
these NGT progressors were significantly higher than
those of the stable NGT participants (5.00 and 5.33 mmol/l,
respectively, p<0.0001 for both).
In comparison with the reference group of stable NGT
individuals, the other three groups presented a remarkably
similar clinical phenotype (higher prevalence of familial
diabetes, older age, and higher waist-to-hip ratio, fasting
and 2 h plasma glucose, fasting and 2 h plasma insulin,
glucagon and proinsulin concentrations) regardless of
whether they were progressors, regressors or stable non-
NGT. Likewise, a metabolic profile characterised by lower
insulin sensitivity and reduced beta cell glucose sensitivity
with increased fasting secretion rate and total insulin output
was common to all these three groups, the differences from
the reference group of stable NGT remaining statistically
significant after adjustment for centre, sex, age and BMI
(Table 2). Accordingly, in the final multivariate logistic
model, both insulin sensitivity and glucose sensitivity were
independent negative predictors of progression to dysgly-
caemia (as were also male sex and rate sensitivity), whereas
waist-to-hip ratio and fasting glucose levels (and, almost
significantly [p=0.06], insulin output) were positively
associated with progression (familial diabetes, age,
BMI, physical activity, smoking, 2 h plasma glucose,
glucagon and proinsulin not being significant indepen-
dent variables in this model; Fig. 1). When added to this
model, the change in BMI between baseline and follow up
was also an independent predictor (with an OR of 1.35
[95% CI 1.11–1.63] for each SD change in BMI
[=4.4 kg]). Neither insulin sensitivity nor glucose sensi-
tivity showed a significant interaction with sex. A nearly
identical pattern was obtained when the group of pro-
gressors was contrasted only with the stable NGT group
(data not shown). Among people who were non-NGT at
baseline (n=119), a positive family history of diabetes was
a negative predictor of regression (OR 0.36 [95% CI 0.13–
0.95]) while insulin sensitivity was a positive predictor
(OR 1.81 [95% CI 1.00–3.28]) after adjusting for centre,
sex, age and BMI.
In the whole dataset, the separate impact of baseline
insulin sensitivity and glucose sensitivity on fasting and 2 h
plasma glucose levels at follow up is depicted in Fig. 2:
both contributed significantly to the latter, only glucose
insensitivity did to the former. Baseline AIR was lower in
the non-NGT groups, although the differences from the
Variable Men (n=471) Women (n=577) p value
Age (years) 43 (14) 45 (12) 0.01
Familial T2DM (%) 27 28 NS
BMI (kg/m2) 25.9 (4.3) 24.0 (5.0) <0.0001
Waist:hip ratio 0.92 (0.08) 0.81 (0.10) <0.0001
Fat mass (%) 22 (8) 33 (10) <0.0001
Fasting glucose (mmol/l) 5.2 (0.6) 5.0 (0.6) <0.0001
Fasting insulin (pmol/l) 32 (24) 30 (20) 0.02
Fasting glucagon (pmol/l) 9.0 (4.0) 7.0 (3.0) <0.0001
Proinsulin (pmol/l) 6.0 (5.0) 5.0 (3.0) <0.0001
HDL-cholesterol (mmol/l) 1.22 (0.37) 1.54 (0.44) <0.0001
LDL-cholesterol (mmol/l) 3.00 (1.00) 2.80 (1.00) <0.0001
Triacylglycerols (mmol/l) 1.07 (0.74) 0.84 (0.47) <0.0001
M/I (μmol min−1[kg FFM]−1[nmol/l]−1) 113 (70) 146 (80) <0.0001
Table 1 Anthropometric and
metabolic characteristics of the
study
Data are median (interquartile
range) for the cohort
T2DM, type 2 diabetes mellitus
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stable NGT group were less marked than was the case for
beta cell glucose sensitivity (Table 2). AIR was inversely
related to insulin sensitivity in a log–log fashion in each of
the four groups, with correlation coefficients ranging from
0.21 to 0.38 (p≤0.04; ESM Fig. 2). In univariate associa-
tion, AIR did not predict progression significantly (OR 0.74
[95% CI 0.51–1.06]); after including insulin sensitivity it
nearly did so (OR 0.70 [95% CI 0.49–1.01]), but failed to
add predictivity to the model in Fig. 2.
At follow up, body weight had increased significantly in
the whole cohort (by 1.0±0.2 kg, range −16 kg to +34 kg);
across groups, the change was significantly greater in the
progressors than in stable NGT participants (Table 3).
Metabolic variables were essentially unchanged in the
stable NGT and stable non-NGT group, while they had
changed in opposite directions in progressors vs regressors.
Thus, fasting and 2 h plasma glucose and insulin levels had
increased in the progressors and decreased in the regressors.
Of the beta cell function variables, insulin sensitivity and
glucose sensitivity decreased in the progressors and
increased in the regressors, whereas fasting insulin secre-
tion rate and total insulin output were reduced in the
regressors and increased in the progressors (Figs 3, 4). By
multiple regression analysis (adjusting for centre, sex,
familial diabetes, age, BMI, waist-to-hip ratio, physical
activity and baseline value of the dependent variable), the
change in fasting glucose (as a continuous variable) was
predicted by baseline glucose sensitivity (p=0.0003, with a
total explained variance of 29%), while the change in 2 h
Table 2 Baseline clinical and metabolic phenotype according to subsequent changes in glucose tolerance
Variable Stable NGT Regressors Stable non-NGT Progressors
n (%) 809 (77) 61 (6) 49 (5) 129 (13)
Sex (M/F) 363/446 23/38 22/27 63/66
Familial diabetes (%)† 25 34 49 33
Age (years)‡ 43 (13) 47 (11) 50 (11) 47 (13)
BMI (kg/m2)‡ 24.5 (4.8) 26.4 (4.6) 26.9 (4.1) 26.1 (5.5)
Waist:hip ratio‡ 0.85 (0.13) 0.86 (0.15) 0.91 (0.13) 0.90 (0.12)
Fasting glucose (mmol/l)‡ 5.0 (0.6) 5.3 (1.0)§ 5.5 (1.1)§ 5.3 (0.8)§
2 h glucose (mmol/l)‡ 5.3 (1.6) 8.2 (0.9)§ 8.4 (1.3)§ 6.1 (1.4)§
Fasting insulin (pmol/l)‡ 29 (20) 39 (28)§ 42 (29)§ 34 (24)§
Fasting glucagon (pmol/l)‡ 8.0 (4.0) 8.0 (4.0) 9.0 (5.3) 10 (4.5)
Proinsulin (pmol/l)‡ 5.0 (4.0) 7.5 (5.0)§ 7.0 (6.0)§ 8.0 (5.8)§
2 h insulin (pmol/l)‡ 131 (125) 307 (237)§ 331 (411)§ 177 (169)§
M/I (μmol min−1[kg FFM] −1 [nmol/l]−1)‡ 137 (84) 97 (88)§ 92 (62)§ 106 (79)§
Glucose sensitivity (pmol min−1 m−2 [mmol/l]−1) 121 (81) 69 (60)§ 68 (44)§ 95 (50)§
OGIS (μmol min−1[kg FFM] −1)‡ 11.8 (3.3) 9.6 (1.9)§ 8.8 (2.4)§ 10.3 (3.2)§
Rate sensitivity (nmol m−2 [mmol/l]−1) 0.83 (1.33) 0.73 (0.88) 0.72 (0.77) 0.69 (1.12)
Potentiation ratio‡ 1.79 (1.33) 1.33 (0.90)§ 1.46 (0.67)§ 1.51 (0.90)§
Fasting insulin secretion (pmol min−1 m−2)‡ 66 (34) 82 (56)§ 96 (55)§ 84 (34)§
Total insulin output (nmol/m2)‡ 38 (16) 45 (19)§ 50 (22)§ 44 (15)§
AIR (n=761) (pmol min−1m−2 [mmol/l]−1)‡ 59 (43) 47 (42)§ 48 (36) 52 (50)
Data are median (interquartile range) for the cohort
† p=0.001 by χ2 ; ‡ p≤0.002 by Kruskal Wallis test; § p<0.001 vs Stable NGT adjusted for centre, sex, age and BMI
M, male; F, female
Insulin output
Rate sensitivity
Glucose sensitivity
Insulin sensitivity
Fasting glucose
Waist:hip ratio
Sex (male) 
0.2 1 2.5
Odds ratio (95% CI)
0.5 0.8 2
Fig. 1 Multiple logistic regression model for deterioration of glucose
tolerance over 3 years of follow up. Odds ratio and 95% confidence
intervals are calculated for 1 SD change in the predictor variable. The
model is adjusted for centre, familial diabetes, age, BMI, physical
activity and 2 h plasma glucose levels
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glucose was predicted by both insulin sensitivity (p<
0.0001) and glucose sensitivity (p=0.04, total explained
variance of 32%).
Discussion
The RISC cohort is comprised of relatively young,
basically healthy European women and men. Over 3 years
of observation, the following main findings were obtained.
First, progressors, regressors and participants whose dys-
glycaemia remained stable shared a common clinical and
metabolic phenotype broadly indicative of risk of incident
diabetes. Thus, not only were they older and heavier, but they
also exhibited hyperinsulinaemia and hyperproinsulinaemia,
insulin resistance and reduced beta cell glucose sensitivity
independently of age and BMI. This result suggests that these
individuals (23% of the participants) may derive from a single
at-risk pool, whose glucose tolerance oscillates over time
between the upper boundary of normality and the diagnostic
range (IFG, IGT or overt diabetes): according to the
categorisation used here, a single follow-up test may capture
them at a peak (progressors) or trough (regressors) while
overall their glucose tolerance is deteriorating over time (i.e.
there were twice as many progressors as regressors).
Second, weight gain significantly added to the prediction
of progression, yielding a separate 35% increase in risk of
dysglycaemia for each 4.4 kg of weight gain. This finding
is in keeping with the well established notion that weight
gain is a potent risk factor for dysglycaemia [23–25].
Third, both baseline insulin sensitivity and beta cell
glucose sensitivity protected against progression indepen-
dently of one another (Fig. 2). Using the dataset including
only progressors and stable NGT (n=941) to estimate the
effect size, we found a similar odds ratio for individuals in
the bottom 25% of insulin sensitivity (median [interquartile
Table 3 Changes in clinical and metabolic variables according to changes in glucose tolerance
Stable NGT Regressors Stable non-NGT Progressors
Δ Body weight (kg)† 0.7 (4.5) −0.1 (5.6) 1.2 (4.6) 1.7 (4.3)‡
Δ BMI (kg/m2)† 0.3 (1.59) 0.1 (2.3) 0.6 (1.7) 0.6 (1.6)‡
Δ Fasting glucose (mmol/l)† 0.10 (0.60) 0.00 (0.74)§ 0.30 (0.62) 0.42 (0.77)§
Δ 2 h glucose (mmol/l)† 0.10 (1.60) −1.74 (2.07)§ 0.25 (1.55) 1.90 (1.80)§
Δ Fasting insulin (pmol/l)† 1 (16) −5 (19)§ −5 (23) 3 (22)
Δ 2 h insulin (pmol/l)† 3 (103) −95 (182)§ −3 (247) 94 (213)§
Δ Rate sensitivity (nmol m−2 [mmol/l]−1) 0.03 (1.37) 0.14 (1.01) −0.01 (0.72) 0.04 (0.97)
Δ Potentiation ratio† −0.06 (1.31) 0.23 (1.16)§ −0.01 (0.92) −0.02 (0.79)
Δ Fasting insulin secretion (pmol min−1 m−2)† 0 (25) −3 (30)§ −10 (29) 7 (33)§
Δ Total insulin output (nmol/m2)† 2 (13) −3 (14)§ 0 (13) 7 (17)§
Data are median (interquartile range) for the cohort
† p≤0.02 by Kruskal Wallis test; ‡ p<0.05 vs Stable NGT adjusted for centre, sex, and age; § p<0.05 vs Stable NGT adjusted for centre, sex, age and BMI
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Fig. 2 Fasting (a) and 2 h
(b) plasma glucose levels at
follow up as predicted by
baseline insulin resistance (M/I
from the clamp) and beta cell
glucose insensitivity (from
modelling of the OGTT),
both grouped into sex-specific
quartiles. M/I quartiles are
I=207 [75]; II=143 [48];
III=117 [45]; IV=78 [34]. Beta
cell glucose sensitivity quartiles
are: I=207 [84]; II=131 [22];
III=96 [19]; IV=58 [20]
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range]: 75 [26] μmol min−1[kg FFM]−1[nmol/l]−1, OR
2.52; 95% CI 1.51–4.21) and for those in the bottom 25%
of beta cell glucose sensitivity (61 [20] pmol min−1m−2
[mmol/l]−1, OR 2.39; 95% CI 1.6–3.93). When using
plasma glucose levels at follow up as the outcome variable,
beta cell glucose insensitivity was a determinant of both
fasting and post-glucose plasma glucose, whereas insulin
resistance was an independent determinant of post-
glucose but not fasting glycaemia. This finding is
consistent with the results obtained using the shift in
glucose tolerance category as the outcome, where IFG
and IGT were pooled together. Also consistent with
expectation is the fact that good insulin sensitivity was a
negative predictor of progression and a positive predictor
of regression (despite the relatively small number of
participants in the regressor group).
Of note is that absolute insulin secretion, whether the
fasting rate or the total post-glucose output, trended in the
opposite direction with regard to insulin sensitivity and beta
cell glucose sensitivity, namely, higher insulin secretion
was associated with progression and lower insulin secretion
tracked with regression. This finding confirms that changes
in absolute insulin secretion rates are adaptive responses to
changes in glucose levels, which are, in turn, primarily
controlled by glucose sensitivity and insulin sensitivity.
Stated otherwise, as beta cell glucose sensitivity deterio-
rates and insulin resistance worsens, plasma glucose rises
and induces enhanced insulin secretion as an attempt to
limit further hyperglycaemia.
A further observation is that, while glucose and insulin
sensitivity changed in parallel during progression (or
regression), they were numerically independent of one
another. Neither in the baseline nor in the follow-up dataset
was there a significant relationship between these two
determinants of glucose tolerance. In contrast, rates of
insulin secretion (fasting and total over the 2 h of the
OGTT) were reciprocally related to insulin sensitivity (data
not shown). We have interpreted this finding to indicate that
the absolute rate of insulin secretion reflects the set point of
beta cell capacity as determined by the level of insulin
sensitivity (and, possibly, by some other feature of obesity)
[22]. Unlike glucose sensitivity, AIR was reciprocally
related to insulin sensitivity (although less strongly than
reported in other studies) [27]; this empirical index,
however, is a hybrid of true beta cell sensitivity and insulin
secretory capacity and shares with the latter the reciprocal
relation to insulin sensitivity [22]. Glucose sensitivity and
rate sensitivity, on the other hand, express the ability of the
beta cell to respond to acute glucose changes by promptly
revving up insulin discharge; as such, these modes of beta
cell function need not be directly influenced by insulin
sensitivity. In fact, when analysing their longitudinal
changes across the full spectrum of glucose tolerance,
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baseline; dark grey bars, follow up
In
su
lin
 se
ns
iti
vi
ty
(m
l m
in−
1  
[k
g F
FM
]−1
)
*
*
Stable NGT Progressors Regressors Stable non-NGT
4
6
8
10
12
14
16
Fig. 3 Insulin sensitivity (as the OGIS index) at baseline and follow
up in the four groups. Bars are median and interquartile range. The
asterisks denote statistical significance (p≤0.05) for the difference
between baseline and follow up (using the Wilcoxon test). Light grey
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Fig. 5 Three-year changes (±SEM) in insulin sensitivity and beta cell
glucose sensitivity in the four groups. The dotted line is an ideal
trajectory of glucose tolerance, from lower (on the left) to higher (on
the right). Squares, baseline; circles, follow up
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glucose sensitivity and insulin sensitivity appear to vary
consensually (Fig. 5).
Finally, the model in Fig. 1 indicates that glucose
sensitivity, rate sensitivity and insulin sensitivity, in that
order, are powerful indicators of risk of dysglycaemia and
replace the quota of risk conveyed by familial diabetes, age,
BMI and physical activity. The waist-to-hip ratio and
fasting glycaemia, however, retain a degree of separate
predictivity. Possibly, a higher waist-to-hip ratio, which
reflects a more central distribution of body fat, carries risk
of dysglycaemia through subclinical inflammation [26, 28,
29]; fasting glycaemia, on the other hand, may mark the
presence of more marked hepatic insulin resistance [30] and
relative hyperglucagonaemia [31, 32].
In summary, this prospective analysis of the RISC cohort
demonstrates that glucose homeostasis deteriorates over
time even in the relatively young and healthy, with more
people progressing to dysglycaemia than regressing from it.
Insulin sensitivity and beta cell glucose sensitivity predict
and track these changes quantitatively, with roughly equal
power. Weight gain, while small on average, carries a
significant independent risk of progression. Progressors,
regressors and IGT/IFG participants have a common
metabolic syndrome-like phenotype, including a degree of
insulin resistance and beta cell glucose insensitivity not
explained by sex, age and BMI. This ‘common soil’ of
metabolic risk may be the phenotypic expression of
enhanced genetic predisposition.
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